Offering a potential antidote to health-care silos that can hamper and delay care, the Enterprise Imaging and Informatics Suite may revamp image sharing and communication between providers.
Offering the promise of secure image sharing, improved workflow efficiencies and enhanced integration with electronic health records (EHRs) and referring provider portals, a new software suite may provide radiologists with an emerging option for medical image management.
Seeking to develop an integrated hub with centralized patient data, Intelerad Medical Systems has launched the Enterprise Imaging and Informatics Suite at the 2022 Healthcare Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition in Orlando, Fla.
Incorporating components from acquired brands ranging from Ambra Health to HeartIT, the Enterprise Imaging and Informatics Suite reportedly facilitates improved interoperability, greater efficiency, and improved communication between providers, according to Intelerad.
“Intelerad’s Enterprise Imaging and Informatics Suite provides hospitals and health systems with an industry-leading enterprise imaging solution,” noted Mike Lipps, the chief executive office for Intelerad. “As demand for managing, sharing and analyzing patient data and images continues to grow, health-care customers need a powerful, scalable, vendor-neutral imaging system that improves overall performance.”
Intelerad says key components of the software suite, among others, include:
• the Clario SmartWorklist™, which enables radiologists to efficiently manage imaging and patient data in one place;
• Ambra Image Exchange, which enhances collaboration between providers through secure transmission of patent images; and
• the Cardiovascular Suite, which features registry alignment, analytics reports and EHR integration.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.